CGEN
Compugen Ltd. · NASDAQ · Healthcare · USD · 20-F for 2025, filed 2026-03-02
Figures on this page computed 2026-11-08 12:32 UTC
Last close
1.96USD
Market data, 2026-11-06
Except where said otherwise: 20-F for 2025, filed 2026-03-02
5.3xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001178913-26-000663
- Reported in
- USD
- computed
- 20-F for 2025, filed 2026-03-02
207.2%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001178913-26-000663
- Reported in
- USD
- 20-F for 2025, filed 2026-03-02
- 20-F for 2025, filed 2026-03-02
- 20-F for 2025, filed 2026-03-02
- 20-F for 2025, filed 2026-03-02
- 20-F for 2025, filed 2026-03-02
- 20-F for 2025, filed 2026-03-02
48.6%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001178913-26-000663
- Reported in
- USD
- 20-F for 2025, filed 2026-03-02
- 20-F for 2025, filed 2026-03-02
43.0%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001178913-26-000663
- Reported in
- USD
- 20-F for 2025, filed 2026-03-02
- 20-F for 2025, filed 2026-03-02
0.03Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001178913-26-000663
- Reported in
- USD
- 20-F for 2025, filed 2026-03-02
- 20-F for 2025, filed 2026-03-02
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
- Growth105.2%97 of 100, above its sector
- Returns on capital207.2%97 of 100, above its sector
- Margins87.3%97 of 100, above its sector
- Price5.3x70 of 100, above its sector
- Safety0.0375 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 0 of 4- Profit on each unit of sales48.6%13.4%Ahead
Higher is better here.
- Return on the capital it uses207%n/an/a
Higher is better here.
- Sales growth over five years105%16.9%Ahead
Higher is better here.
- Debt against equity0.03n/an/a
Lower is better here.
- Gross margin87.3%64.3%Ahead
Higher is better here.
- Price against earnings5.3x9.4xAhead
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against Niagen Bioscience Inc, CGEN is behind on 0 of 4 measures.
Against Niagen Bioscience Inc, CGEN is behind on 0 of 4 measures.
Every figure in this lens
Except where said otherwise: 20-F for 2025, filed 2026-03-02
Profit on each unit of sales48.6%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001178913-26-000663
- Reported in
- USD
Return on the capital it uses207.2%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001178913-26-000663
- Reported in
- USD
Sales growth over five years105.2%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001178913-26-000663
- Reported in
- USD
Debt against equity0.03
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001178913-26-000663
- Reported in
- USD
Gross margin87.3%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001178913-26-000663
- Reported in
- USD
Price against earnings5.3x
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001178913-26-000663
- Reported in
- USD